Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

A Common Genetic Variant and the Risk of Prostate Cancer

Publish date:: May 10, 2019

Key clinical point: The Kallikarein-related peptidase 3 (KLK3) gene may play a role in prostate cancer risk.

Major finding: Higher levels of prostate-specific antigen (PSA) with KLK3 polymorphism in prostate cancer patients indicate that rs2735839 polymorphism could be a risk factor.

Study details: A case-control study of 532 patients with prostate cancer and 602 controls with benign prostate hyperplasia.

Citation:

Motamedi RK, et al. J Cell Biochem. 2019 Apr 24. doi: 10.1002/jcb.28743.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,